New strategies in platelet inhibition in noncoronary interventions

Seminars in Vascular Surgery

Volumn 14, Issue 2, 2001, Pages 143-149

  Tepe, Gunnar ^a   Hahn, Ulrich ^a   Pusich, Benjamin ^a   König, Claudius ^a   Müller Schimpfle, Markus ^a   Raygrotzki, Sabine ^a   Claussen, Claus D ^a   Duda, Stephan H ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; RETEPLASE; TICLOPIDINE;

ARTERY INJURY; DRUG ACTIVITY; ENDOVASCULAR SURGERY; FIBRINOLYSIS; HUMAN; PHARMACODYNAMICS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

EID: 0035015437     PISSN: 08957967     EISSN: None     Source Type: Journal    
DOI: 10.1053/svas.2001.23171     Document Type: Review

References (26)

1. The antiplatelet effects of ticlopidine and clopidogrel
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
3. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
4. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy
5. Prevention and treatment of thrombembolic and ischemic complications associated with endovascular procedures: Part I - Pathophysiological and pharmacological features
6. Arterial response to mechanical injury: Balloon catheter de-endothelization
7. Passivation of metallic stents after arterial gene transfer of ph VEGF165 inhibits thrombus formation and intimal thickening
8. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions
9. Basilar artery rethrombosis: Successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor
10. Abciximab in acute ischemic stroke. A randomized double-blind, placebo-controlled, dose-escalation study
11. Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis
12. Use of glycoprotein IIb/IIIa antagonist (abciximab) in peripheral vascular interventions
13. Acute peripheral arterial occlusion: Predictors of success in catheter-directed thrombolytic therapy
14. Basic and clinical aspects of fibrinolysis and thrombolysis
15. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction
16. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
17. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
18. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis
19. Randomised comparison of streptokinase vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
20. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral artery thrombosis
21. Intraarterial thrombolysis of lower extremity occlusions: Prospective, randomized comparison of forced periodic infusion and conventional slow fusion
22. Monoclonal antibody c7E3 Fab as an adjunct for thrombolysis of peripheral arteries
23. Glycoprotein IIb/IIIa blockade during peripheral artery thrombolysis. Results of the PROMPT phase II trial platelet receptor antibodies in order to manage peripheral thrombosis
24. Platelet glycoprotein IIb/IIIa receptor antagonists in peripheral artery disease
25. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 Trial
26. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction